Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Description

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Conditions

Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Condition
Differentiated Thyroid Gland Carcinoma
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject has biopsy-proven papillary or follicular thyroid cancer
  • * Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan
  • * Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan
  • * Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent)
  • * Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min)
  • * Age 18 or older
  • * Ability to understand a written informed consent document, and the willingness to sign it
  • * Subject is not pregnant
  • * Contrast-enhanced CT within 4 last weeks
  • * Amiodarone within last 4 months
  • * Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks
  • * Unable to lie flat, still or tolerate a PET scan
  • * Applied betadine, iodoform, or quick tanning products to skin within last two weeks
  • * If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25
  • * Taken anti-thyroid medication within 1 week
  • * Subject is breastfeeding
  • * Positive pregnancy test

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Stephen M. Broski, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

2026-05-01